Effects of dalcetrapib in patients with a recent acute coronary syndrome.

By G. Schwartz, A. Olsson, M. Abt, Christie M. Ballantyne, P. Barter, J. Brumm, Bernard R. Chaitman, I. Holme, D. Kallend, Lawrence A Leiter and 7 more. New England Journal of Medicine, 2012

1,972 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. (2016, background): “tients who had experienced a recent ACS, the CETP inhibitor dalcetrapib did not reduce the risk of recurrent CV events.(362)”
Cardiovascular Effects and Benefits of Exercise (2018, background): “Although higher levels of HDL are associated lower CVD risk (16, 17), recent work suggests that some pharmacological interventions that elevate plasma HDL levels fail to reduce the risk of major cardiovascular events (18, 19).”
Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator (2016, background): “On the contrary, although HDL-c is observationally inversely associated with CAD risk, interventions to raise HDL-c concentrations (Schwartz et al., 2012) and focused Mendelian randomization investigations (Voight et al.”
2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. (2019, background): “Neither clinical study was able to show any clinical benefit associated with CETP inhibitors.(65) More recently, the REVEAL study investigated anacetrapib in >30 000 patients with atherosclerotic vascular disease and resulted in a lower incidence of MACE compared with placebo after 4 years, with no ”